PHOSIMMUNE
PhosImmune is a clinical-stage biotechnology company developing therapeutic cancer vaccines. PhosImmune controls a library of unique, aberrantly phosphorylated tumor antigens (PTAs) that are directly implicated in metastasis, meeting a pressing need for high quality tumor antigens for use in new and more effective cancer vaccines.
PHOSIMMUNE
Industry:
Biotechnology Clinical Trials
Founded:
2012-01-01
Address:
Charlottesville, Virginia, United States
Country:
United States
Website Url:
http://www.phosimmune.com
Total Employee:
51+
Status:
Closed
Contact:
434-981-4995
Total Funding:
0
Technology used in webpage:
Google Font API Domain Not Resolving CloudFront Pound Sterling
Current Employees Featured
Founder
Investors List
Virginia Venture Partners
Virginia Venture Partners investment in Venture Round - PhosImmune
More informations about "PhosImmune"
PhosImmune Company Profile 2024: Valuation, Investors
PhosImmune General Information Description. Operator of a cancer immunotherapy company intended to commercialize a library of phosphopeptide tumour targets. The company engages …See details»
PhosImmune - Products, Competitors, Financials, Employees, …
PhosImmune’s neoantigens have unique advantages in cancer immunotherapy. The company’s phosphopeptide tumor targets (PTTs) are fragments of proteins expressed in cancer cells. …See details»
PhosImmune - Contacts, Employees, Board Members, Advisors
PhosImmune, a Charlottesville-based clinical-stage biotechnology companySee details»
PhosImmune - VentureRadar
PhosImmune Inc. is developing cancer vaccines based on a class of aberrantly phosphorylated antigens that are directly involved in cellular transformation and/or metastasis. The company …See details»
PhosImmune, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore PhosImmune, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»
PhosImmune - Ownership and Business Overview - Mergr
PhosImmune is a life science company. Life Science M&A Summary in 2015. Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2015. The largest life science …See details»
Cancer Immunotherapy, PhosImmune, Drug Development …
PhosImmune, Inc. is a cancer immunotherapy company located in Charlottesville, VA and Birmingham, UK, founded to commercialize library of phosphopeptide tumor antigens (PTAs) …See details»
PhosImmune - Tech Stack, Apps, Patents & Trademarks
PhosImmune, a Charlottesville-based clinical-stage biotechnology companySee details»
PhosImmune | Washington, D.C., DC, USA Startup - gust.com
PhosImmune is a immunotherapy co. developing cancer vaccines using its platform technology of over 400 unique phosphopeptide tumor antigens Find investment information and connect with …See details»
PhosImmune - Company Profile - Tracxn
PhosImmune - Developer of therapeutics cancer vaccines.. Raisedfunding over 1 round from 1 investor. Founded by Dean L. Fanelli, Mark Cobbold and 1 other in the year 2012. …See details»
PhosImmune - Tech Company Profile - Gaebler.com Venture …
PhosImmune is a clinical-stage biotechnology company developing therapeutic cancer vaccines. PhosImmune controls a library of unique, aberrantly phosphorylated tumor antigens (PTAs) …See details»
Agenus (PhosImmune Inc.) • UVA Licensing & Ventures Group
PhosImmune has developed a proprietary PTT screening methodology which allows for rapid identification and selection of PTTs for therapeutic applications. Agenus is an immuno …See details»
Agenus Acquires PhosImmune for Up to $44.9M - genengnews.com
Dec 24, 2015 Agenus paid PhosImmune’s equity holders $2.5 million in upfront cash and $7.4 million in shares of Agenus common stock valued at approximately $4.54 per share at the …See details»
PhosImmune - Funding, Financials, Valuation & Investors
Aug 12, 2014 PhosImmune, a Charlottesville-based clinical-stage biotechnology company. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. …See details»
PhosImmune - Gust
PhosImmune PhosImmune is a immunotherapy co. developing cancer vaccines using its platform technology of over 400 unique phosphopeptide tumor antigens. Stage Product In …See details»
Agenus Acquires PhosImmune - Technology Networks
Jan 4, 2016 PhosImmune’s neoantigens have unique advantages in cancer immunotherapy. The company’s phosphopeptide tumor targets (PTTs) are fragments of proteins expressed in …See details»
PhosImmune and PureMHC LLC To Co-Discover And Co-Develop …
Oct 29, 2014 A new set of antibody-based immunotherapies that mimic T cell receptors (TCRms) to target cancers will be developed by PhosImmune Inc. and Pure MHC LLC, which …See details»
Donald Hunt - President & Scientific Founder @ PhosImmune
Donald Hunt, Ph.D., is the President of PhosImmune and a Scientific Founder. Dr. Hunt is a Chaired Professor of Chemistry and Pathology at the University of Virginia. He earned a B.S. …See details»